Piperidines

Details Piperidines Piperidines

2007-07-17

2007-07-17

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S199000

Reexamination Certificate

active

10286662

ABSTRACT:
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels. More particularly, the invention provides substituted piperidines, and compositions containing these compounds. Also provided are methods using the compounds of the invention for the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrance of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a channel that includes a PN3 subunit.

REFERENCES:
patent: 3910930 (1975-10-01), Janssen et al.
patent: 3989707 (1976-11-01), Janssen et al.
patent: 4344948 (1982-08-01), Takai et al.
patent: 4470989 (1984-09-01), Henning et al.
patent: 5492918 (1996-02-01), Wild et al.
patent: 6506738 (2003-01-01), Yu et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 2002/0128288 (2002-09-01), Kyle et al.
patent: 2003/0073842 (2003-04-01), Urbanski et al.
patent: 0905512 (1999-03-01), None
patent: WO 00/26203 (2000-05-01), None
patent: WO 00/69819 (2000-11-01), None
patent: WO 01/05770 (2001-01-01), None
patent: WO 01/66525 (2001-09-01), None
Greene “Protective groups in organic synthesis” Wiley-intersci. pub. p. 218, 220-221, 251, 272-273 (1982).
Janssen et al. “1-(1-[2-(1,4-benzodioxa-2-yl) . . . ” CA 81:120644 (1974).
Ozaki et al. “Preparation of 1-oxoimidazole . . . ” CA 130:52418 (1998).
Soskic et al. “Synthesis and characterization . . . ” CA 117:124706 (1992).
Sawada et al. “Benzimidazolone derivatives . . . ” CA 134:100871 (2001).
Ito et al. “4-(2-keto-1-benzimidazolinyl) . . . ” CA 131:102281 (1999).
Ishigaki et al. “Amino acid derivatives . . . ” CA 2003:767774 (2003).
Takayama et al. “Preparation of quinoxalin . . . ” CA 139:149653 (2003).
Ting et al. “preparation of1-(4-piperidinyl)benzimidazolones . . . ” CA 140:27826 (2003).
Greene “Protective groups in organic synthesis” Wiley-intersci. p. 218. 220-221. 251, 272-273 (1982).
Soskic “Synthesis and characterization . . . ” CA 117:124706 (1992).
Sawada “Benzimidazolone derivatives . . . ” CA 124:100871 (2001).
Ishigaki “Amino acid derivatives . . . ” CA 2003:767774 (2003).
Takayama et al “Preparation of quinoxaline . . . ” CA 139:149653 (2003).
Janssen et al. “1-(1-[2-(1,4-benzodioa-2yl . . . ” CA 81:120644 (1974).
Ozaki “Preparation of oxoimidazole . . . ” CA 130:52418 (1998).
Ito “4-(2-keto-1-benzylimidazolinyl . . . ” Ca 131:102281 (1999).
Rmond et al. “Pharmacological profile of a novel series of NK1 . . . ” CA 128:162735 (1998).
Gross et al. “Preparation of . . . ” CA 138:368892 (2003).
892-package.
Madge, “Sodium Channels: Recent Developments and Therapeutic Potential”,Ann. Rep. Med. Chem.33:51-60 (1998).

Affiliated with

Also associated with

Rating

Piperidines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3814469